In short
Pralatrexate is an anti-cancer drug that has shown promise in treating various types of T-cell lymphomas, particularly in patients whose cancer has returned or not responded to other treatments. This article summarizes key findings from clinical trials investigating pralatrexate alone and in combination with other drugs for peripheral T-cell lymphoma (PTCL) and other T-cell malignancies.
At a glance
- Main Use
- Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)
- Mechanism of Action
- Blocks folic acid production in cancer cells, inhibiting their growth
- Administration
- Intravenous infusion, typically weekly for 6 weeks in a 7-week cycle
- Common Dosage
- 30 mg/m² (may vary in different trials)
- Response Rates
- 25-54% in various trials for PTCL
- Common Side Effects
- Mucositis, low blood cell counts, nausea, fatigue
- Combination Studies
- With romidepsin, pembrolizumab, erlotinib, and others
- Key Outcomes Measured
- Overall response rate, progression-free survival, overall survival
What is Pralatrexate?
Pralatrexate is a medication used in the treatment of certain types of cancer, particularly blood cancers. It is also known by its brand name Folotyn and has several other names in scientific literature, including PDX, 10-propargyl-10-deazaaminopterin, and (RS)-10-propargyl-10-deazaaminopterin. This drug was developed to target specific cancer cells and interfere with their growth and spread.
How Pralatrexate Works
Pralatrexate belongs to a class of drugs called antifolates. It works by blocking the body's ability to make folic acid, a protein that cancer cells need to grow and multiply. By interfering with this process, pralatrexate can help slow down or stop the growth of cancer cells. It's important to note that while the drug blocks folic acid production in cancer cells, patients are often given folic acid supplements to help reduce side effects in healthy cells.
Conditions Treated with Pralatrexate
Pralatrexate is primarily used to treat several types of blood cancers, including:
- Peripheral T-cell Lymphoma (PTCL): This is a group of aggressive blood cancers that develop from mature T-cells, a type of white blood cell.
- Cutaneous T-cell Lymphoma (CTCL): A type of cancer that affects the skin.
- Non-Hodgkin's Lymphoma: A broader category of blood cancers that includes PTCL.
Research is also being conducted to explore its effectiveness in treating other types of cancers, such as non-small cell lung cancer.
How Pralatrexate is Administered
Pralatrexate is typically given as an intravenous (IV) injection, which means it's delivered directly into a vein. The most common dosing schedule is:
- Once a week for 6 weeks, followed by 1 week of rest. This 7-week period is called a treatment cycle.
- The injection is usually given over a short period, typically 3-5 minutes.
- The dose is often based on body surface area, with a common starting dose being 30 mg/m².
Patients receiving pralatrexate are also typically given vitamin B12 injections and daily folic acid supplements to help reduce side effects.
Clinical Trials and Research
Pralatrexate has been and continues to be the subject of numerous clinical trials. These studies aim to:
- Determine the most effective dosage and schedule.
- Evaluate its effectiveness in different types of cancers.
- Assess its performance compared to or in combination with other cancer treatments.
- Study its effects in specific patient populations, such as Asian patients with PTCL.
These trials help researchers better understand how pralatrexate can be used most effectively to treat various cancers.
Potential Side Effects
Like all medications, pralatrexate can cause side effects. Some of the most common side effects observed in clinical trials include:
- Mucositis: Inflammation and ulceration of the mucous membranes lining the digestive tract.
- Hematological toxicities: These include low white blood cell count (neutropenia), low platelet count (thrombocytopenia), and anemia.
- Fatigue
- Nausea and vomiting
- Skin reactions
Your healthcare team will monitor you closely for these and other side effects and may adjust your treatment as needed.
Combination Therapies
Researchers are exploring the use of pralatrexate in combination with other cancer treatments to potentially enhance its effectiveness. Some combination therapies being studied include:
- Pralatrexate with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), a common chemotherapy regimen.
- Pralatrexate with romidepsin, another drug used to treat T-cell lymphomas.
- Pralatrexate with pembrolizumab, an immunotherapy drug.
- Pralatrexate with erlotinib, a drug used in some lung cancers.
These combination therapies are still being studied to determine their safety and effectiveness compared to single-drug treatments.